Fatty Liver (MASLD) Reversal: The Low-Carb and Lifestyle Evidence

By Dr. Leandro Pucci, DCN, CNS, CKNS, LDN

 

Fatty liver disease affects roughly one in three adults worldwide (1), and in its early stages it is one of the most reversible conditions in metabolic medicine. Losing 10% of body weight resolved the inflammatory form of the disease in 90% of patients in a biopsy-based study. Carbohydrate restriction reduces liver fat faster than calorie restriction alone, even at the same weight loss. Most people with fatty liver have no symptoms, so the first step is knowing to look.

 

In my practice, fatty liver is often the missing piece behind insulin resistance, stubborn triglycerides, and abdominal weight gain. The liver is where metabolic dysfunction often starts, and where diet acts fastest.

 

 

What MASLD Is, and Why the Name Changed

 

In 2023, international liver societies renamed nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease, or MASLD (2). The new name defines the condition by what causes it rather than by what it is not. A diagnosis requires excess liver fat plus at least one cardiometabolic risk factor, such as excess waist circumference, elevated glucose or A1c, high blood pressure, high triglycerides, or low HDL.

 

The inflammatory form is called MASH (formerly NASH). MASH can progress to fibrosis (scarring), cirrhosis, and liver cancer. Fibrosis stage, not fat alone, is what predicts long-term liver outcomes.

 

 

How Fat Gets Into the Liver

 

A classic tracer study in people with fatty liver mapped where liver fat comes from (3):

  • About 59% from fatty acids released by fat tissue into the blood. Insulin resistance in fat tissue increases this flow.
  • About 26% from de novo lipogenesis, the liver converting carbohydrate into new fat. This pathway is driven by high insulin and by sugar, especially fructose from sweetened drinks and refined foods.
  • About 15% from dietary fat directly.

This breakdown explains why carbohydrate quality and quantity matter so much for the liver, and why improving insulin sensitivity is central. It also shows that fatty liver is not simply a matter of eating fat.

 

Alcohol adds to the load, since the liver prioritizes clearing it over burning fat. The new nomenclature includes a category (MetALD) for people with both metabolic risk and meaningful alcohol intake.

 

 

Tests to Ask For

 

Liver enzymes are a good starting point when evaluating fatty liver, but a normal ALT does not necessarily rule it out. Several tests can provide a more complete picture of liver health.

 

ALT, AST, and GGT measure liver cell stress and may be mildly elevated, although results can sometimes remain normal. Triglycerides and fasting insulin can help identify increased liver fat production and insulin resistance.

 

The FIB-4 score is calculated using age, AST, ALT, and platelet count to estimate the risk of advanced liver fibrosis. A score below 1.3 generally suggests a low risk of advanced fibrosis (4).

 

An ultrasound can detect moderate to severe liver fat, but it is less sensitive for detecting mild fat accumulation. Another option is vibration-controlled transient elastography (FibroScan), which measures liver stiffness to assess fibrosis and uses CAP to estimate liver fat.

 

American liver guidelines recommend using FIB-4 as an initial screening tool for people with metabolic risk factors. If the score is elevated, follow-up testing with elastography is recommended (4). If you have type 2 diabetes, prediabetes, or abdominal obesity, consider asking your physician to calculate your FIB-4 score.

 

 

What the Evidence Shows for Reversing Fatty Liver

 

Weight loss, with a clear dose-response

In a study of 293 patients with biopsy-proven steatohepatitis followed for a year of lifestyle change, outcomes tracked closely with the amount of weight lost. Among those who lost 10% or more of body weight, 90% had resolution of steatohepatitis and 45% had regression of fibrosis (5). Even 5% made a meaningful difference: 58% of those patients had resolution.

 

Carbohydrate restriction works faster than calorie restriction

In a two-week study, adults with fatty liver followed either a carbohydrate-restricted diet (under 20 grams a day) or a calorie-restricted diet. Weight loss was similar, about 4 to 5 kg in both groups, but liver fat fell by 55% with carbohydrate restriction versus 28% with calorie restriction (6). A separate study using an isocaloric low-carbohydrate, higher-protein diet showed rapid falls in liver fat with no change in calories, driven by a sharp drop in de novo lipogenesis and a rise in fat burning in the liver (7).

 

Exercise helps, even without weight loss

A meta-analysis found that regular exercise reduced liver fat even when body weight changed little (8). Both aerobic and resistance training contribute, and the effect adds to dietary change.

 

 

A Phased Plan for Fatty Liver Reversal

 

I build this in stages so each change is sustainable before the next one starts.

  1. Remove the biggest liver loads first. Sugar-sweetened drinks, fruit juice, and alcohol. This step alone often moves ALT and triglycerides within weeks.
  2. Lower refined carbohydrate and set a protein floor. I individualize carbohydrate level to insulin sensitivity; for many patients with fatty liver, a well-formulated low-carb approach is the most effective option. Protein at each meal protects muscle during weight loss.
  3. Choose fats deliberately. Olive oil, avocado, nuts, and fatty fish rather than fried and ultra-processed foods. Vegetables and fiber-rich foods support the gut-liver connection; my article on dietary fiber covers how I individualize this.
  4. Move daily and train for strength. A combination of walking and two to three resistance sessions per week.
  5. Protect sleep and address stress. Both influence insulin resistance and appetite regulation.
  6. Retest. Liver enzymes, triglycerides, and fasting insulin at about 12 weeks; imaging or elastography at 6 to 12 months if it was abnormal at baseline.

 

Where Medications Fit

 

Two drugs are now FDA-approved for MASH with moderate to advanced fibrosis (but not cirrhosis), both to be used alongside diet and exercise. Resmetirom, a liver-targeted thyroid hormone receptor agonist, was approved in 2024 after a phase 3 trial showed higher rates of steatohepatitis resolution and fibrosis improvement than placebo (9). Semaglutide received accelerated approval for MASH in August 2025 (11). In its phase 3 trial, steatohepatitis resolved in 62.9% of patients on semaglutide versus 34.3% on placebo, and fibrosis improved in 36.8% versus 22.4% (10).

 

These are important options for people with established fibrosis. For the much larger group with simple fatty liver or early MASH, nutrition and lifestyle remain first-line, and they address the drivers that medication does not. The GLP-1 post in this series covers how to protect muscle and nutrient status if you do start semaglutide.

 


 

Frequently Asked Questions

 

Can fatty liver be reversed?

Yes, especially before significant fibrosis develops. Weight loss of 5% to 10%, reduced sugar and refined carbohydrate, and regular exercise reduce liver fat and inflammation, and larger weight loss can reverse fibrosis in some people.

 

How long does it take to reverse fatty liver?

Liver fat can fall substantially within two weeks of carbohydrate restriction. Liver enzymes usually improve within one to three months. Fibrosis changes take longer, often a year or more.

 

What is the best diet for fatty liver?

The strongest short-term evidence supports reducing carbohydrate, particularly sugar and refined starch, while keeping protein adequate. A Mediterranean-style pattern also has good evidence. The best diet is the one you can sustain that lowers liver fat on retesting.

 

Can I have fatty liver with normal liver enzymes?

Yes. Many people with fatty liver have normal ALT. Imaging, elastography, or a FIB-4 calculation gives a better picture when metabolic risk factors are present.

 

What does MASLD stand for?

Metabolic dysfunction-associated steatotic liver disease, the 2023 replacement for the term NAFLD.


Concerned about your liver enzymes or a fatty liver finding? I help patients identify what is driving liver fat and build a plan that brings the numbers down. Book a discovery call or learn more about my approach to metabolic health.

 

This article is for educational purposes and is not medical advice.


References

  1. Riazi K, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. PMID: 35798021
  2. Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. PMID: 37363821
  3. Donnelly KL, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343-1351. PMID: 15864352
  4. Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. PMID: 36727674
  5. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378. doi:10.1053/j.gastro.2015.04.005
  6. Browning JD, Baker JA, Rogers T, et al. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr. 2011;93(5):1048-1052. doi:10.3945/ajcn.110.007674
  7. Mardinoglu A, Wu H, Bjornson E, et al. An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans. Cell Metab. 2018;27(3):559-571. doi:10.1016/j.cmet.2018.01.005
  8. Keating SE, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57(1):157-166. PMID: 22414768
  9. Harrison SA, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497-509. PMID: 38324483
  10. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. doi:10.1056/NEJMoa2413258
  11. FDA approves semaglutide (Wegovy) injection 2.4 mg for noncirrhotic MASH. HCPLive. August 15, 2025. hcplive.com


You might also like...

Nutrigenomics Testing in Practice What Your Genes Can and Can't Tell You About Nutrition
By Dr. Leandro Pucci, DCN, CNS, CKNS, LDN A nutrigenomic test can tell you how your body is likely to handle specific nutrients: how fast you ...
Read More →
How to Boost Wellness with Simple Self-Improvement Steps You Can Start Now
For busy parents juggling work and wellness, the biggest frustration is often feeling stuck between good intentions and inconsistent follow-through...
Read More →
Smart Batch Cooking for Weeks That Never Slow Down
Smart Batch Cooking for Weeks That Never Slow DownMeal prepping is a practical response to crowded calendars and decision fatigue, not a rigid life...
Read More →
Precision Metabolic Optimization: Harnessing Nutrigenomics and Functional Lab Panels for Personalized Nutrition
The "one-size-fits-all" approach to metabolic health has failed the American population. Despite decades of adherence to generalized dietary guidel...
Read More →